By Luc Cohen
NEW YORK, March 3 (Reuters) - Gilead Sciences GILD.O set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into the drugmaker's promotional speakers program for HIV drugs.
The Foster City, California-based company disclosed the potential resolution with the Manhattan U.S. Attorney's office in a Friday afternoon securities filing.
Gilead said it had received a subpoena in 2017, but did not provide additional details about the probe in its filing.
The company, which first disclosed the probe in 2018, said in a statement on Monday: "We have taken a litigation accrual for a potential settlement."
A spokesman for the Manhattan U.S. Attorney's office declined to comment.
Promotional speaker programs in which doctors are paid by drugmakers to deliver lectures about their products have drawn past Justice Department scrutiny.
In 2020, Swiss drugmaker Novartis NOVN.S paid more than $600 million to settle with the Manhattan U.S. Attorney over claims its speaker program was a cover for paying bribes to doctors to prescribe its medication.
Novartis at the time said it was "committed to doing what is right" and had established an enhanced compliance framework.
Gilead's HIV drug sales rose 16% to $5.45 billion in the fourth quarter of 2024, contributing to a surge in its share price.
The company expects to launch a new drug, lenacapavir, for protecting against HIV infection later this year.
(Reporting by Luc Cohen in New York; Editing by Bill Berkrot)
((luc.cohen@thomsonreuters.com; +1 646 361 1622; Reuters Messaging: Twitter: @cohenluc))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。